<DOC>
	<DOCNO>NCT00686881</DOCNO>
	<brief_summary>The objective study compare efficacy peginterferon alfa-2b ( PegIFN-2b ) monotherapy administer dose 0.5 ug/kg v strong neo minophagen C ( SNMC ) participants chronic hepatitis C ( CHC ) liver fibrosis ( Metavir fibrosis score F2 F3 ) previously treat interferon . The trial evaluate effect treatment progression liver fibrosis , liver inflammation , liver function . Treatment administer 156 week 4-week follow-up .</brief_summary>
	<brief_title>Efficacy Peginterferon Alfa-2b ( SCH 054031 ) v Glycyrrhizin Interferon ( IFN ) -Treated Patients With Chronic Hepatitis C F2/F3 Liver Fibrosis ( P04773 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Glycyrrhetinic Acid</mesh_term>
	<criteria>Patients chronic hepatitis C previously treat interferon At least 20 year age Liver fibrosis score rat F2 F3 base result liver biopsy screen Female patient willing use contraception Body weight 35.0 kg 110.0 kg ( inclusive ) Positive hepatitis C virus ribonucleic acid ( HCVRNA ) qualitative assay Patients meet follow laboratory criterion : Serum alanine aminotransferase ( ALT ) level : &gt; 60 IU/L Neutrophil count : &gt; =1,200/mm^3 Platelet count : &gt; =100,000/mm^3 Serum potassium level : &gt; =3.5 mEq/L Patients receive interferon therapy within 90 day Screening Patients receive antiviral agent antitumor agent , immunomodulator therapy ( include chronic glucocorticoid radiotherapy ) within 90 day Screening ( exclude local administration topical use ) Patients receive investigational drug within 90 day Screening Hepatitis B surface antigen ( HBs ) positive Antinuclear antibody titer 1:320 high Creatinine level exceed upper limit reference range measure screen test 2 ; Fasting blood glucose level &gt; =126 mg/dL Patients insulin therapy regardless fast blood glucose level Patients concurrent past history follow condition : liver cirrhosis , liver failure , liver carcinoma ; hepatic encephalopathy , esophageal varix require treatment , ascites ; suicidal attempt ideation ; epileptic seizure require drug therapy ; angina pectoris , heart failure , myocardial infarction fatal arrhythmia ; autoimmune disease ( Hashimoto 's disease [ chronic thyroiditis ] , Crohn 's disease , ulcerative colitis , rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , etc . ) ; malignant tumor ( permitted register patient least 5 year cure ) . Patients concurrently follow condition : liver disease autoimmune hepatitis , alcoholic liver injury , druginduced hepatitis ; hemophilia ; depression schizophrenia require treatment ; hypertension control drug therapy arrhythmia require treatment , chronic pulmonary disease ; abnormal thyroid function control drug therapy ; organ transplant ( corneal , hair transplant , etc . ) ; aldosteronism , myopathy , hypokalemia . Patients history hypersensitivity interferon preparation biological product vaccines Patients history hypersensitivity monoammonium glycyrrhizinate , glycine , Lcysteine monohydrochloride ; Women pregnant lactating , woman pregnancy rule base result serum human chorionic gonadotropin ( HCG ) measurement Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis C</keyword>
</DOC>